Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The TAR DNA-binding protein 43 (TDP-43) mRNA iron-responsive element (IRE) is a highly conserved RNA stem-loop structure located within the 5' untranslated region (UTR) of the TARDBP transcript [1]. This element functions as a post-transcriptional regulatory sensor that binds Iron Regulatory Proteins (IRP1 and IRP2) to control the translation of TDP-43 in response to cellular iron levels [1,2]. Under low-iron conditions, IRPs bind to the IRE and physically block the recruitment of the 43S pre-initiation complex, thereby inhibiting translation; conversely, high iron levels trigger IRP dissociation, leading to increased TDP-43 protein production [2,3]. In neurodegenerative conditions like Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Lobar Degeneration (FTLD), the dysregulation of TDP-43 levels and its subsequent aggregation are hallmark features of pathogenesis [3,4]. Therapeutic candidates such as buntanetap (ANVS401) target this IRE to suppress the translation of TDP-43 and other neurotoxic proteins, aiming to restore proteostasis and reduce neurodegeneration [5]. This regulatory element represents a significant target for small molecule intervention in proteinopathies where protein overexpression drives disease progression [4,5]. Sources: [1] PubMed: 30639114; [2] PubMed: 33434134; [3] UniProt: Q13148; [4] NIH/NCBI Gene: 23435; [5] Annovis Bio Pipeline Documentation.
Modulation of mRNA translation by stabilizing the interaction between Iron Regulatory Proteins (IRPs) and the iron-responsive element (IRE) in the 5' UTR, thereby sterically hindering ribosomal assembly and reducing protein synthesis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on TAR DNA-binding protein 43 mRNA iron-responsive element (TDP-43 mRNA IRE).